VCM
KYMR icon

Versant Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Versant Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
101
+91
+910% +$7.82K ﹤0.01% 2182
2026
Q1 		$833 Buy
+10
New +$792 ﹤0.01% 2675
2025
Q2 		– Sell
-83
Closed -$2.27K – 2686
2025
Q1 		$2.27K Buy
+83
New +$3.03K ﹤0.01% 2255

Other funds holding KYMR

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

Versant Capital Management's KYMR Position: Q2 2026 in Review

Versant Capital Management increased its Kymera Therapeutics (KYMR) stake by 910% in Q2 2026, buying an estimated $7.82K and bringing the position to 101 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2182.

Versant Capital Management first reported a position in KYMR in Q1 2025 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Versant Capital Management held 101 shares of Kymera Therapeutics worth $11.6K as of Q2 2026.
  • Versant Capital Management bought 91 Kymera Therapeutics shares in Q2 2026, an estimated $7.82K.
  • Kymera Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2182 holding.
  • Versant Capital Management first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.